The Republican Specialized Scientific-Practical Medical Centre of Therapy and Medical Rehabilitation; Tashkent, Uzbekistan.
*Corresponding author: Umida K. Kamilova, PhD, ScD. The Republican Specialized Scientific-Practical Medical Centre of Therapy and Medical Rehabilitation; Tashkent, Uzbekistan. E-mail: firstname.lastname@example.org
Published: December 23, 2014.
The purpose of the present research was to study the comparative influence of lisinopril and losartan on the parameters of cardiac hemodynamics and kidney function state in CHF (Congestive Heart Failure) patients with NYHA Functional Class (FC) I-III.
Material and Methods: The study included 92 CHF patients between the ages of 41 and 75 (mean age 66.3±9.8 yrs) with FCI-III of ischemic genesis. The patients were divided into two groups. Group I consisted of 47 CHF patients with FCI-III who had been receiving losartan for 6 months in addition to standard therapy. Group II consisted of 45 CHF patients with FCI-III who had been receiving lisinopril for 6 months in addition to standard therapy. The dose of losartan was 50–100 mg/day, and lisinopril, 5–10 mg/day. The control group included 20 healthy volunteers. NYHA FC was determined by the 6-minute walk test (6MWT) and the Russian scale of evaluation of the clinical condition of the patients. All patients underwent clinical examination, ECG, and echocardiography. Estimated creatinine clearance rate (eCCr) was calculated using the Cockcroft-Gault formula; estimated glomerular filtration rate (eGFR) was calculated using the MDRD (Modification of Diet in Renal Disease) formula.
Results: The results obtained show a clear association between maladaptive LV remodeling and kidney dysfunction at CHF. Our analysis revealed the significant direct correlation between EF and eGFR, as well as between 6MWT and eGFR. The 6-month therapy of CHF patients with NYHA FCI-III based on a combination of standard therapy with ACEi/ARB has resulted in a significant improvement in the cardiac hemodynamic, LV myocardial contractility, and renal function, with a more significant effect in the patients treated with losartan.
- Belenkov Yu. Chronic heart failure. M.: GEOTAR-MEDIA; 2009.
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33:1635-1701.
- van der Velde M, Matsushita K, Coresh J et al, Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79(12):1341-52.
- Arutyunov G. Pathophysiological processes in kidneys at the patients with CHF. Serdechnaya nedostatochnost 2008; 5(49):234-249.
- Damman K. Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure. J Renal Care 2010; 36:18–26.
- Soni S, Fahuan Y, Ronco C, Cruz D. Cardiorenal syndrome: biomarkers linking kidney damage with heart failure. J Biomarkers Med 2009; 3(5):549-560.
- KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int (Suppl.) 2013; 3:1-150.
- Keyhan G, Chen S, Pilote L. Angeotensin converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail 2007; 9(67):594-601.
- Jason P, Pharm D. Are all angiotensin receptor blockers created equal in themanagement of heart failure? PharmaNote 2012; 27(5):1-8.
- Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantification of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358–367.
- Sahn DJ, Demaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072–1083.
- Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1979; 70: 1308–1316.
- Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison with necropsy findings. Am J Cardiol 1986; 57: 450–458.
- Arutyunov AG. ACE Inhibitors in CHF: Necessity despite the Change of Goals. Difficult patient 2014; 5:1-8; http://t-pacient.ru.
- Ruggenenti P, Remuzzi G. Worsening kidney function in decompensated heart failure: treat the heart, don’t mind the kidney. Eur Heart J 2011; 32(20): 2476–2478.
- Meune C, Wahbi K, Duboc D, Weber S. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function. J Cardiovasc Pharmacol Ther 2011; 16 (3-4):368-75.
The fully formatted PDF version is available.
IJBM 2014; 4(4):218-221. © 2014 International Medical Research and Development Corporation. All rights reserved.